← Back to Search

Monoclonal Antibodies

open-label for Atopic Dermatitis

Phase 4
Waitlist Available
Led By Jonathan Bernstein
Research Sponsored by Jonathan A. Bernstein, MD
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
history of adult onset atopic dermatitis
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up after 6 months
Awards & highlights

Study Summary

This trial looked at the effectiveness of a new drug, dupilumab, in treating atopic dermatitis. The study found that the drug was effective in improving the clinical symptoms of the disease.

Eligible Conditions
  • Atopic Dermatitis

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~after 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and after 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary objective of this study is to correlate cutaneous transcriptomes with before and after Dupilumab treatment outcomes in patients who meet the clinical diagnostic criteria for adult onset AD.
Secondary outcome measures
To investigate possible influence of Dupilumab on serologic protein biomarkers in patients with adult onset AD

Trial Design

1Treatment groups
Experimental Treatment
Group I: open-labelExperimental Treatment1 Intervention
open-label
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab Prefilled Syringe
2020
Completed Phase 4
~20

Find a Location

Who is running the clinical trial?

Jonathan A. Bernstein, MDLead Sponsor
1 Previous Clinical Trials
12 Total Patients Enrolled
Jonathan BernsteinPrincipal InvestigatorBernstein Clinial Research Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants may join this experiment?

"Yes, the evidence on clinicaltrials.gov suggests that this medical study is actively recruiting participants. The trial was announced on September 1st 2020 and updated most recently in February 28th 2022; 12 patients are required from a single centre."

Answered by AI

Is participation in this investigation open?

"Currently, 12 patients aged 19-75 with a history of adult onset atopic dermatitis are being recruited for this eczema trial."

Answered by AI

Has a trial of this nature been conducted previously?

"Presently, 49 studies regarding this therapeutic intervention are being conducted in 436 cities and 43 nations. Sanofi initiated the first trial back in 2015 with 880 participants; it has since completed its Phase 3 clinical trials stage. Since then, 54 researches have been done on it altogether."

Answered by AI

What potential risks or adverse effects are associated with this therapy?

"A score of 3 was assigned to this treatment's safety, due to its Phase 4 designation which demonstrates that it has been approved for use."

Answered by AI

Is this research endeavor currently seeking participants?

"Affirmative. Per records on clinicaltrials.gov, this study is currently accepting patients; the trial was initially posted on September 1st 2020 and most recently revised in February 2021. The research requires 12 participants to be enrolled at a single site."

Answered by AI

What type of health issue does this therapy typically address?

"This treatment regimen has been demonstrated to be effective at managing dermatitis, atopic conditions, corticosteroid therapy-resistant diseases, and eosinophil associated disorders."

Answered by AI

Has there been any prior research with respect to this treatment methodology?

"At the moment, 49 clinical trials are assessing this treatment's efficacy with 13 being in their third phase. While a number of these experiments stem from Palo Alto, there is an astonishing 2602 locations running such research worldwide."

Answered by AI

Does this trial extend its enrollment to those in the geriatric age range?

"This experiment is limited to those aged 19-75. Patients outside of this age range may find applicable trials in the 118 clinical experiments designed for minors and 202 studies that focus on elderly participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Jonathan A. Bernstein, MD 2020. "The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04358224.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top